Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 20
Opinion
Video
Adoption of New Treatments for BCG-Unresponsive NMIBC
Author(s):
A panelist discusses how the ability to administer newer non–muscle-invasive bladder cancer (NMIBC) treatments in local urology practices rather than specialized oncology centers reduces patient burden and travel requirements while suggesting that increased education and support could help more health care providers adopt these treatment options.
- From an operational standpoint, how important is it that these treatments can be administered by urologists locally, without the need to refer patients to oncology centers? Please discuss the overall burden on patients, systemic adverse effects, and the need to travel to specialized centers.
- What strategies would you recommend to encourage more health care practitioners to adopt newer treatment modalities for BCG-unresponsive NMIBC?
Related Videos
Related Content
